8-K current report · filed Jun 30, 2026

COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K Current Report: June 30, 2026

Item EX-99.1Item EX-99.2Item EX-99.3COLL overview

Short answer

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on June 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Going-concern warning: recurring losses, net capital deficiency, and funding needs create substantial doubt within 12 months.

COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis

AI summary of each reported item and its exhibits

Item EX-99.1 · Exhibit EX-99.1

  • Going-concern warning: recurring losses, net capital deficiency, and funding needs create substantial doubt within 12 months
  • 2025 product sales increased to $113.6M from $79.6M, but operating cash flow remained negative at $105.0M
  • Cash and equivalents fell to $13.9M from $47.9M, while current debt reached $100.8M
  • Net loss improved to $42.4M from $153.8M, aided by commercial and administrative expense reductions
  • Severe concentration risk: a single customer represented over 97% of accounts receivable and AZSTARYS® drives product revenue

Item EX-99.2 · Exhibit EX-99.2

  • Corium’s Q1 2026 statements support Collegium’s AZSTARYS acquisition completed May 12, 2026, with future viability tied to Collegium liquidity
  • Net sales $24.6M, up from $19.3M, while operating loss narrowed to $4.6M from $12.2M
  • Net loss $11.6M, improved from $20.4M, but operating cash burn remained $18.6M
  • $60.0M member contribution funded liquidity, alongside $45.0M patents and licensing-rights payments
  • $101.3M current term debt matures September 1, 2026, creating near-term refinancing or repayment pressure

Item EX-99.3 · Exhibit EX-99.3

  • AZSTARYS acquisition closed May 12, 2026 for $655.6M cash, with potential milestone payments up to $135.0M
  • Financing added $300.0M of delayed-draw debt, increasing pro forma term notes payable to $813.6M
  • Pro forma 2025 revenue $893.8M, but net loss $56.6M after acquisition amortization and financing costs
  • Pro forma March 2026 revenue $218.1M and net loss $3.9M, including $67.9M intangible amortization
  • Preliminary purchase accounting includes $551.8M of acquired intangible assets and $74.6M goodwill, subject to revision

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings

Get the next COLL 8-K as it lands

Follow COLL for push alerts, or ask the research agent what this filing means.